Academic history
Elizabeth Budde, MD, PhD, obtained her Bachelor of Medicine from Tongji Medical University Wuhan, Hubei, China, in 1995 and then obtained her MD and PhD from the Duke University of Medicine, Durham, NC, qualifying in 2001. Dr Budde completed her residency at the Washington University School of Medicine, St. Louis, MO, in 2006, and then went on to complete her fellowship at the University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA.
Dr Budde was an Attending Physician at the Lymphoma Clinic and Hematopoietic Cell Transplant Service, Seattle Cancer Care Alliance, Seattle, WA, as well as an Acting Instructor in the Department of Medicine at the University of Washington, Seattle, WA, between 2009-2013. Dr Budde is now a Staff Physician and Associate Professor in the Division of Lymphoma at the Department of Hematologic Oncology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
Dr Budde has received various awards, namely the Edson Immunotherapy Pilot Award (2010-2012), Margaret E. Early Medical Trust Fund (2013-2015), and the Greg Wiviott and Sharon & Robert Wiviott Seed grant, Stop Cancer Foundation (2016). She also holds membership to various professional societies such as the American Society of Hematology and the Chinese American Faculty Association in Southern California, where she served as President in 2016.
Speaking on novel lymphoma and leukemia therapeutics
Dr Budde’s research focuses on the development of novel therapeutics such as immunotherapies for lymphoma and leukemia, with recent publications on the use of mosunetuzumab for the treatment of multiply relapsed follicular lymphoma.
Dr Budde is Principal Investigator for various clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy particularly in the relapsed/refractory setting such as the Phase I/II ALEXANDER trial (NCT03287817) looking at CD19/22 CAR T-cells for diffuse large B-cell lymphoma (DLBCL) as well as a Phase II trial (NCT04484012) investigating modified immune cells and acalabrutinib for relapsed/refractory mantle cell lymphoma.
